Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
111 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02449135 | Nano Drug Interventional Therapy Using Digital Subtraction Angiography(DSA) for Pancreatic Carcinoma | no longer available | — | — | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 9, 2021 | clinicaltrials |
| NCT02329106 | Percutaneous Irreversible Electroportion in Unresectable Liver Cancer Close to Diaphragmatic Dome | completed | N/A | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02332551 | Percutaneous Irreversible Electroporation to Treat Liver Cancer Close to the Gallbladder | completed | N/A | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02333773 | Irreversible Electroporation(IRE) For Unresectable Portal Venous Tumor Emboli(IRE) | completed | N/A | 15 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02335112 | Irreversible Electroporation(IRE) For Unresectable Head and Neck Neoplasms(IRE) | completed | N/A | 15 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02335827 | Irreversible Electroporation(IRE) For Unresectable Renal Tumors(IRE) | completed | N/A | 15 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02340858 | Percutaneous Irreversible Electroportion for Unresectable Breast Cancer | completed | N/A | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02343835 | Anti-Tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer | completed | N/A | 20 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02352935 | Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver Function | completed | N/A | 15 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02425059 | Irreversible Electroporation(IRE) For Unresectable Rectal Neoplasms | completed | N/A | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02430597 | Irreversible Electroporation(IRE) For Unresectable Hilus Pulmonis Neoplasms(IRE) | completed | N/A | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02430610 | Irreversible Electroporation(IRE) For Uterine Cervical Neoplasms(IRE) | completed | N/A | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02430623 | Irreversible Electroporation(IRE) For Unresectable Urinary Bladder Neoplasms(IRE) | completed | N/A | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02430636 | Irreversible Electroporation(IRE) For Unresectable Stomach Neoplasms(IRE) | completed | N/A | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02430662 | Irreversible Electroporation(IRE) For Unresectable Gallbladder Neoplasms(IRE) | completed | N/A | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02430675 | Irreversible Electroporation(IRE) For Unresectable Laryngeal Neoplasms(IRE) | completed | N/A | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02430688 | Irreversible Electroporation(IRE) For Unresectable Extremities Neoplasms(IRE) | completed | N/A | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02430701 | Irreversible Electroporation(IRE) For Unresectable Esophageal Neoplasms(IRE) | completed | N/A | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02430753 | Irreversible Electroporation(IRE) For Lung Neoplasms Accompanied by Respiratory Function Insufficiency(IRE) | completed | N/A | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02430766 | Irreversible Electroporation(IRE) For Unresectable Lymph Node Metastases(Close to Nerve)(IRE) | completed | N/A | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02430779 | Irreversible Electroporation(IRE) For Unresectable Renal Pelvic and Ureteral Neoplasms(IRE) | completed | N/A | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT04393220 | Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma | completed | Phase 2 | 60 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02981719 | Simultaneous Gemcitabine and Irreversible Electroporation for Locally Advanced Pancreatic Cancer | completed | N/A | 61 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT03180437 | Safety and Efficiency of IRE Plus γδ T Cell Against Locally Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 62 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Nov 2, 2020 | clinicaltrials |
| NCT03484962 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer | withdrawn | Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03501056 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer | withdrawn | Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03509298 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer | withdrawn | Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03524261 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer | withdrawn | Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03524274 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Colorectal Cancer | withdrawn | Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03540199 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer | withdrawn | Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03554395 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Gastric Cancer | withdrawn | Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03818347 | Hydrogen Gas for Cancer Rehabilitation | completed | N/A | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02857920 | Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 45 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 14, 2020 | clinicaltrials |
| NCT02547948 | CD19-targeting CAR T Cells for B Cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT02547961 | Chimeric Antigen Receptor-Modified T Cells for Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT02575261 | CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients | withdrawn | Phase 1 / Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT02723942 | CAR-T Cell Immunotherapy for HCC Targeting GPC3 | withdrawn | Phase 1 / Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT03252171 | CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients | withdrawn | Phase 1 / Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT04406610 | CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients | withdrawn | Phase 1 / Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 0 | Jul 16, 2020 | clinicaltrials |
| NCT03183206 | Safety and Efficiency of γδ T Cell Against Breast Cancer | completed | Phase 1 / Phase 2 | 100 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jul 13, 2020 | clinicaltrials |
| NCT03183219 | Safety and Efficiency of γδ T Cell Against Liver Cancer | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jul 13, 2020 | clinicaltrials |
| NCT03183232 | Safety and Efficiency of γδ T Cell Against Lung Cancer | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jul 13, 2020 | clinicaltrials |
| NCT02843204 | Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 110 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT02430649 | Irreversible Electroporation(IRE) For Unresectable Prostatic Neoplasms(IRE) | withdrawn | N/A | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | May 27, 2020 | clinicaltrials |
| NCT02744664 | Cryotherapy Combine Icotinib for Advanced NSCLC Treatment | completed | Phase 4 | 60 | Fuda Cancer Hospital, GuangzhouOTHER | 0 | May 27, 2020 | clinicaltrials |
| NCT02115958 | The Immunotherapy of Nasopharyngeal Cancer Using Cancer Stem Cells Vaccine | completed | Phase 1 / Phase 2 | 40 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02176746 | A Phase I/II Study of Active Immunotherapy With Cancer Stem Cells Vaccine for Colorectal Cancer(CSC) | completed | Phase 1 / Phase 2 | 40 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02178670 | Safety and Effectivity Immunotherapy to Treat Ovarian Cancer With Cancer Stem Cells Vaccine | completed | Phase 1 / Phase 2 | 40 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02338752 | Safety and Efficacy Study of Mix Vaccine in Pancreatic Carcinoma Patient | completed | Phase 1 / Phase 2 | 20 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02425748 | Safety and Efficiency of γδ T Cell Against Non Small Lung Cancer ( Without EGFR Mutation) | completed | Phase 1 / Phase 2 | 40 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials